Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Stiolto

- PMLiVE

Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes

The insulin is designed as an alternative to daily basal insulin

- PMLiVE

Johnson & Johnson’s multiple myeloma treatment approved by US FDA

The approval was based on phase 3 data showing survival rates of 83.3% after three years

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

GSK’s Nucala approved by MHRA for uncontrolled COPD

Symptoms of COPD include breathlessness, persistent cough and frequent chest infections

- PMLiVE

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

In 2022, nearly one million new patients were diagnosed with gastric cancer

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

- PMLiVE

Merck to expand respiratory disease portfolio with $10bn Verona acquisition

The deal includes a drug approved in the US for chronic obstructive pulmonary disease

- PMLiVE

UK researchers uncover first new asthma and COPD attack treatment in 50 years

The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD

Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease

- PMLiVE

GSK announces positive late-stage results for IL-5 inhibitor Nucala in COPD

The chronic respiratory disease affects more than 300 million people globally

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EMA for uncontrolled COPD in adults

Approximately 220,000 COPD patients in the EU could be eligible for Dupixent treatment

- PMLiVE

New syndicated COPD report now available

Living with COPD 2023

Inizio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links